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The Cancer Genome Atlas (TCGA): Breast and Ovarian Cancers
Laura Ann Riccio 
Faculty Sponsor: Dr. Niall G. Howlett
Introduction to Genomics
A genome is the complete ordered sequence of  DNA bases (A, C, G, T) 
which make up all of  the protein- and RNA-coding genes, and regulatory 
sequences necessary for the construction of  an organism. The field of  
genomics began in the 1970’s when Walter Fiers and his team in Ghent, 
Belgium sequenced the genome of  the M2 bacteriophage.
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Significant Genomic Sequencing Events from 1993-2005
First fungus: 
Saccharomyces 
cerevisiae
(baker’s yeast)
12.1 Mbp
Human Genome Project
HGP was an international, collaborative research program with the goal to 
sequence and map the full human genome of  3 billion base pairs to gain a 
better understanding of  all of  the genes that are present. It was initiated 
in 1990 and a draft sequence was published in 2003, paving the way for 
the development of  new genomics-based research projects.
The Cancer Genome Atlas
The National Institutes of  Health (NIH) and the National Human Genome 
Research Institute (NHGRI) initiated a pilot project called The Cancer 
Genome Atlas (TCGA) in 2006. The overall goal of  TCGA is to catalog all of  
the significant genomic changes in the major types and subtypes of  
cancer. It is hoped that this catalog of  information will serve as a critical 
resource for the prevention, diagnosis, and treatment of  these cancers.
Genes Mutated in HGS-OvCa
Genes Type of  Mutation(s) No. of  Mutated
Samples
Percent of  
Mutations
TP53 Missense 302 96%
RB1 Missense 6 2%
NF1 Missense 13 4%
BRCA1 Germline, somatic 11 3%
CSMD3 Missense 19 6%
CDK12 Nonsense, indel, 
missense 
9 3%
FAT3 Missense 19 6%
GABRA6 Missense 6 2%
BRCA2 Germline, somatic 10 3%
Genes Mutated in Breast Cancer mRNA Subtypes
Genes Luminal A 
(n=225)
Luminal B 
(n=126)
HER2-
enriched 
(n=57)
Basal-
like 
(n=93)
PIK3CA 45% 29% 39% 9%
MAP3K1 13% 5% 4% 0%
GATA3 14% 15% 2% 2%
TP53 12% 29% 72% 80%
CDH1 9% 5% 5% 0%
MAP2K4 7% 2% 2% 0%
PTEN 4% 4% 2% 1%
AKT1 4% 2% 2% 0%
RB1 0.4% 3% 0% 4%
MLL3 8% 6% 7% 5%
TBX3 3% 4% 0% 1%
RUNX1 5% 2% 4% 0%
CBFB 2% 2% 2% 0%
AFF2 1% 2% 5% 4%
PIK3R1 0.4% 2% 4% 0%
PTPN22 0.4% 2% 5% 0%
PTPRD 2% 4% 4% 1%
NF1 2% 4% 0% 2%
CTCF 4% 2% 2% 1%
FOXA1 2% 2% 2% 0%
SF3B1 3% 0% 4% 1%
NCOR1 5% 2% 0% 2%
CDKN1B 1% 1% 2% 0%
What Has Evolved From This?
One of  the most significant findings from TCGA was that basal-like 
breast cancer subtype is most similar to HGS-OvCa, containing similar 
types and frequencies of  mutations. These results suggest that the 
two cancers may have a similar molecular origin, and may be 
responsive to similar therapies. 
Predominant similarities:
• High frequency of  TP53 mutations
• Inactivation of  BRCA1
• Amplification and high expression of  cMYC
• Loss of  RB1
TCGA Breast & Ovarian Cancers
The Illumina next-generation sequencing platform was used for both 
high-grade serous ovarian cancer (HGS-OvCa) and breast cancer. It 
uses a sequencing by synthesis (SBB) technology which incorporates 
four fluorescently-labeled nucleotides to sequence DNA clusters. 
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First archaeon: 
Mathanococcus
jannaschii
1.7 Mbp
First bacterium: 
Haemophilus
influenzae
1.8 Mbp
First plant: 
Arabidopsis 
thaliana (thale
cress)
119 Mbp
First animal: 
Caenorhabditis elegans
(nematode worm)
100 Mbp
Drosophila 
melanogaster 
(fruit fly) 
genome 
165 Mbp
Mus
muscularis
(mouse) 
genome 
sequenced
3.48 Bbp
First egg-laying 
genome: Gallus gallus
(red jungle fowl)
1 Bbp
Homo 
sapiens
(me & you) 
genome 
sequenced
3.2 Bbp
Pan 
troglodytes
(chimpanzee)
3.3 Bbp
Next-Generation Sequencing 
Illumina Next-Generation DNA 
Sequencing 
First, genomic DNA is purified and 
fragmented into <500 bp 
fragments. Universal adaptor 
sequences are ligated to the 
fragments. Fragments are then 
immobilized on a solid support. 
Solid phase amplification is then 
used to produce clonally amplified 
DNA clusters. A single-stranded 
DNA template is created through a 
priming and bridge amplification 
process, ultimately resulting in the 
production of  clonally amplified 
DNA clusters. DNA clusters are 
denatured, adaptor primers are 
added, and DNA polymerase adds 
fluorescently labeled nucleotides 
to the growing polynucleotide 
chain. Insertion of  a 
complementary nucleotide results 
in the emission of  a fluorescent 
signal, which is collected by a 
detector.   
Key: Estrogen receptor (ER) and human epidermal growth factor receptor 
2 (HER2) are cell surface proteins that bind to hormones such as estrogen 
and epidermal growth factor, respectively, in tissues such as the uterus 
and breast. Progesterone receptor (PR) is a protein found in the 
cytoplasm of  breast epithelial cells, that binds to the hormone 
progesterone. These proteins regulate cell division and proliferation. 
